

Fig. S1: Significantly mutated genes affected by SNVs and CNVs in the validation cohort. (A)

Mutations in significantly mutated genes previously described in melanoma and other cancers of the validation cohort. (B) CNVs of selected melanoma-associated genes in the validation cohort: gain (red), gain and mutation (gain with SNV or Indel, dark red), loss ($CN \le 1$, green), loss and mutation (dark green). The primary sites of acral melanoma are shown below (nail apparatus melanoma (NAM) and non-nail acral melanoma (NNAM) in hand or foot).